From Yahoo Finance: 2025-06-17 13:33:00

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the best NASDAQ stocks under $50 to buy. Goldman Sachs analysts gave it a Buy rating with a $37.00 price target, citing promising Phase 1 data for its chronic myeloid leukemia solution. ELVN-001 showed a 47% cumulative major molecular response rate, outperforming Novartis’ Scemblix by 10% and 32%. The company plans to launch a Phase 3 trial in 2026, representing a $3 billion opportunity.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has shown exceptional growth, with a three-year return of 1,980.18% compared to the market’s 64.53%. Headquartered in Boulder, Colorado, the clinical-stage biopharmaceutical company focuses on developing small-molecule inhibitors to help cancer patients. While ELVN shows potential as an investment, other AI stocks may offer greater upside with less risk.

A biologist in a laboratory examining a microscope for small molecule inhibitors.



Read more at Yahoo Finance: Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data